Alvotech fundraises $300m to bolster biosimilar development

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/Sitthiphong)
(Image: Getty/Sitthiphong)

Related tags: Biosimilars, development, Manufacturing, Biologics, facility, Investment, equity

Alvotech raised $300m through a private bond offering and is set to use the earnings to continue the growth of its biosimilar pipeline.

The company’s current product pipeline consists of six biosimilar monoclonal antibodies for the treatment of cancer, autoimmune diseases, and inflammatory diseases.

In a statement, Robert Wessmen, founder of Alvotech said that the $300m (€263m) financing transaction will help fund the company’s plans for future growth – securing the financing of biosimilar development, and clinical studies.

He further said that results of this development will “bring significant potential for healthcare providers around the world to drive healthcare savings and expand patient access to high-quality biosimilars.”

Biosimilar production and development will occur at the company’s new manufacturing facility​ in Reykjavik, Iceland. The facility was a $250m investment by the company in 2013.

Alvotech stated that it has worked to develop itself into a fully integrated biopharmaceutical company with capabilities in cell line development of biosimilars, manufacturing, clinical development, and registrations.

Additional agreements

Aside from the recent fundraising efforts of Alvotech, Japan-based Fuji Pharma will acquire 4.2% equity in the company as of January 2019.

This equity acquisition came after the two companies entered a partnership agreement to further expand Alvotech’s presence in the Asia-Pacific region. Through this partnership, Alvotech will be able to commercialize its biosimilar pipeline in Japan.

Additionally, in September 2018, Alvotech entered a joint-venture agreement with Changchun High & New Technology Industries – the arrangement was valued at $200m. The collaboration will see the creation of a biologics drugs manufacturing facility in Changchun, China. 

Related topics: Biosimilars, Bio Developments, Cell lines

Related news

Show more

Related products

show more

How Viral Safety Testing Will Evolve

How Viral Safety Testing Will Evolve

Viral Safety for mAb: Prevent, Detect, Remove | 20-May-2020 | Event Programme

The pressure to shorten delivery times and reduce costs for biologics are driving an evolution in the biomanufacturing space. Many of the methods used...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more